WO2023150724A3 - Antigen binding proteins that bind b7-h3 - Google Patents

Antigen binding proteins that bind b7-h3 Download PDF

Info

Publication number
WO2023150724A3
WO2023150724A3 PCT/US2023/061996 US2023061996W WO2023150724A3 WO 2023150724 A3 WO2023150724 A3 WO 2023150724A3 US 2023061996 W US2023061996 W US 2023061996W WO 2023150724 A3 WO2023150724 A3 WO 2023150724A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
binding proteins
methods
bind
antigen binding
Prior art date
Application number
PCT/US2023/061996
Other languages
French (fr)
Other versions
WO2023150724A2 (en
Inventor
Andreas Herrmann
Damien Bresson
Heyue Zhou
Weiqun SHEN
Original Assignee
Sorrento Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics, Inc. filed Critical Sorrento Therapeutics, Inc.
Publication of WO2023150724A2 publication Critical patent/WO2023150724A2/en
Publication of WO2023150724A3 publication Critical patent/WO2023150724A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present disclosure provides B7-H3 binding proteins, particularly anti-B7-H3 antibodies, or antigen-binding portions thereof, that specifically bind B7-H3 and uses thereof. Various aspects of the anti-B7-H3 antibodies relate to antibody fragments, single-chain antibodies, pharmaceutical compositions, nucleic acids, recombinant expression vectors, host cells, and methods for preparing and using such anti-B7-H3 antibodies. Methods for using the anti-B7-H3 antibodies include in vitro and in vivo methods for binding B7-H3 and treating diseases associated with B7-H3 expression.
PCT/US2023/061996 2022-02-04 2023-02-03 Antigen binding proteins that bind b7-h3 WO2023150724A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263306938P 2022-02-04 2022-02-04
US63/306,938 2022-02-04

Publications (2)

Publication Number Publication Date
WO2023150724A2 WO2023150724A2 (en) 2023-08-10
WO2023150724A3 true WO2023150724A3 (en) 2023-09-14

Family

ID=87553042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/061996 WO2023150724A2 (en) 2022-02-04 2023-02-03 Antigen binding proteins that bind b7-h3

Country Status (1)

Country Link
WO (1) WO2023150724A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130309233A1 (en) * 2012-05-17 2013-11-21 Sorrento Therapeutics Inc. Antigen Binding Proteins that Bind EGFR
US20190010230A1 (en) * 2014-08-08 2019-01-10 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20220017620A1 (en) * 2018-11-09 2022-01-20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Anti-b7-h3 antibody, preparation method therefor, conjugate and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130309233A1 (en) * 2012-05-17 2013-11-21 Sorrento Therapeutics Inc. Antigen Binding Proteins that Bind EGFR
US20190010230A1 (en) * 2014-08-08 2019-01-10 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20220017620A1 (en) * 2018-11-09 2022-01-20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Anti-b7-h3 antibody, preparation method therefor, conjugate and application thereof

Also Published As

Publication number Publication date
WO2023150724A2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
RU2580020C2 (en) Method for reducing antibody heterogeneity and method for producing related antibodies
MX2022009306A (en) Cd28 single domain antibodies and multivalent and multispecific constructs thereof.
BR112022001923A2 (en) Antigen binding protein, isolated nucleic acid, recombinant host cell, pharmaceutical composition, antigen binding protein production method
MX2021010281A (en) Antigen binding proteins that bind bcma.
JP2008511337A5 (en)
JOP20200313A1 (en) Dll3-cd3 bispecific antibodies
MX2022000652A (en) Claudin18 antibodies and methods of treating cancer.
RU2012143793A (en) SPECIFIC TWO-VALVE ANTIBODIES ANTI-VEGF / ANTI-ANG-2
BRPI0507433B8 (en) recombinant monoclonal antibody or antigen-binding part thereof, composition, isolated nucleic acid, expression vector, and, kit
BR112022001902A2 (en) Bispecific antigen-binding protein, isolated nucleic acid, recombinant host cell, pharmaceutical composition and method for producing the bispecific antigen-binding protein
Ahmadzadeh et al. Anti-HER2 scFv expression in Escherichia coli SHuffle® T7 express cells: effects on solubility and biological activity
FI3250592T3 (en) Anti-transthyretin antibodies
MX2022013894A (en) Neutralizing antibodies that bind the sars-cov-2 s protein.
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
WO2019241893A3 (en) Anti-her3 antibody and uses thereof
MX2022010665A (en) Antibodies binding il4r and uses thereof.
WO2022006451A3 (en) Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies
MX2021011330A (en) Claudin-6 antibodies and drug conjugates.
WO2021173896A8 (en) Materials and methods for modulating an immune response
Li et al. Nanobody against PDL1
MX2023005386A (en) Monoclonal antibodies directed against programmed death-1 protein and their use in medicine.
MX2022014243A (en) St2 antigen binding protein.
MX2022003432A (en) Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability.
BR112022014574A2 (en) HETERODIMERIC PROTEIN, ACTIVABLE ANTIBODY, ONE OR MORE NUCLEIC ACIDS, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION AND METHODS FOR PREPARING A HETERODIMERIC PROTEIN OR AN ACTIVABLE ANTIBODY AND TO TREAT A DISEASE
WO2023150724A3 (en) Antigen binding proteins that bind b7-h3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23750472

Country of ref document: EP

Kind code of ref document: A2